Fig 3. D₂-dopaminergic receptor-mediated regulation of hepatic CYP1A2.

Assessments of the effects induced by the selective dopamine D₂-antagonist sulpiride (SULP) on CYP1A2 relative mRNA expression by using quantitative PCR assays, on CYP1A2 apoprotein levels by using Western blotting, and on CYP1A2-catalyzed MROD activity by using a fluorometric assay. Bonferroni’s correction and Tukey post-hoc tests took place in the comparisons of the data presented here (C vs SULP, C vs B[a]P and B[a]P vs (B[a]P+SULP)). Numbers in the western blot captures indicate the relative CYP1A apoprotein expression following treatment compared to the control expression level that was set at 1. C: controls treated with normal saline; SULP: sulpiride (dopamine D₂-antagonist); B[a]P: benzo[a]pyrene; OIL: olive oil; *P<0.05, **P<0.01, ***P<0.001.